| 1 |
Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
Paul S. S. Aisen, Serge G. Gauthier, Steven H. Ferris et al. · Archives of Medical Science
Open access |
2011 |
294 |
| 2 |
Effect of tramiprosate in patients with mild-to-moderate alzheimer's disease: Exploratory analyses of the MRI sub-group of the alphase study
Serge G. Gauthier, Paul S. S. Aisen, Steven H. Ferris et al. · The journal of nutrition health & aging
Open access |
Jun 2009 |
135 |
| 3 |
BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration
D. Garceau, Nathalie Chauret · Pulmonary Pharmacology & Therapeutics
|
20 Mar 2019 |
102 |
| 4 |
4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome.
Lucie Jetté, Laurent Harvey, Karen Eugeni et al. · PubMed
|
Apr 2009 |
70 |
| 5 |
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Linda Stein Gold, Kim Alexander Papp, David M. Pariser et al. · Journal of the American Academy of Dermatology
|
31 Jul 2021 |
57 |
| 6 |
Scales as outcome measures for Alzheimer's disease
Ronald S. Black, Barry Greenberg, J. Michael Ryan et al. · Alzheimer s & Dementia
Open access |
26 Jun 2009 |
52 |
| 7 |
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)
John A. Smith, Surinder Singh Birring, Michael S. Blaiss et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
5 Mar 2025 |
39 |
| 8 |
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience
Daniel Saumier, Paul S. S Aisen, Serge G. Gauthier et al. · The journal of nutrition health & aging
Open access |
Apr 2009 |
35 |
| 9 |
Investigation of the noncovalent interactions between anti-amyloid agents and amyloid β peptides by ESI-MS
Éric Martineau, Janna M. de Guzman, L.M. Rodionova et al. · Journal of the American Society for Mass Spectrometry
|
2 Jun 2010 |
32 |
| 10 |
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document
Melinda Gooderham, Chih-ho Hong, Lorne E. Albrecht et al. · Journal of Cutaneous Medicine and Surgery
Open access |
Nov 2018 |
24 |
| 11 |
Camlipixant in Refractory Chronic Cough: A Phase 2a, Randomized Controlled Trial (RELIEF)
John A. Smith, Alyn H. Morice, Surinder Singh Birring et al. · American Journal of Respiratory and Critical Care Medicine
Open access |
5 Mar 2025 |
11 |
| 12 |
Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm2 on the chest: A phase 3 randomized controlled trial
C. William Hanke, Lorne E. Albrecht, Torsten Skov et al. · Journal of the American Academy of Dermatology
|
30 Jul 2019 |
11 |
| 13 |
Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Chih-ho Hong, Melinda Gooderham, Lorne E. Albrecht et al. · Journal of Cutaneous Medicine and Surgery
Open access |
Nov 2018 |
9 |
| 14 |
Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial
Linda Stein Gold, Kim Alexander Papp, David M. Pariser et al. · Journal of the American Academy of Dermatology
Open access |
27 Oct 2022 |
3 |
| 15 |
Chronic Cough Medical Journey of Participants in a Phase 2b Study for Refractory Chronic Cough
Mandel Sher, John A. Smith, Michael S. Blaiss et al. · Journal of Allergy and Clinical Immunology
|
Feb 2023 |
2 |
| 16 |
Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses
Nathalie Chauret, D. Garceau, Laurent Harvey et al. · The Journal of Clinical Pharmacology
Open access |
Aug 2026 |
0 |
| 17 |
The Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants
Imran Satia, Anju Tripathi Peters, Nathalie Chauret et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2025 |
0 |
| 18 |
The Impact of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants
Anju Tripathi Peters, Imran Satia, Nathalie Chauret et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2025 |
0 |
| 19 |
Camlipixant diminue le fardeau de l’incontinence urinaire liée à la toux chez des patients atteints de toux chronique réfractaire (TOCRI) dans une analyse post-hoc d’un essai de phase 2b
Venkateswaran K. Iyer, Silvia Demoulin‐Alexikova, Peter V. Dicpinigaitis et al. · Revue des Maladies Respiratoires Actualités
|
2025 |
0 |
| 20 |
Burden of Cough in Refractory Chronic Cough Patients Enrolled in A Phase 2b Study of the P2X3 Antagonist BLU-5937
Alan B. Goldsobel, Michael S. Blaiss, Mandel Sher et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2023 |
0 |
| 21 |
25996 Safety of tildrakizumab 100 mg and 200 mg through 5 years of exposure in reSURFACE 2
Lorne E. Albrecht, George Han, Wendy Cantrell et al. · Journal of the American Academy of Dermatology
|
7 Aug 2021 |
0 |
| 22 |
106 BLU-5937, A Potent and Selective P2X3 Antagonist, For the Treatment of Chronic Itch: Evidence from Pre-Clinical Studies
Nathalie Chauret, Ariel R. Ase, Philippe Séguéla et al. · Journal of Investigative Dermatology
Open access |
Sep 2019 |
0 |